Market Overview
The GCC diabetes care devices market size reached USD 848.2 Million in 2025. The market is projected to expand significantly, with expectations to reach USD 1,664.2 Million by 2034. This growth is driven by rising lifestyle-related disorders, significant advancements in diagnostic tools, proactive health policies, growing demand for modernized treatment options, public awareness campaigns, preventive care emphasis, integration of high technology, and a growing trend toward seamless, patient-centric solutions in diabetes management. The forecast period spans 2026-2034, with a compound annual growth rate (CAGR) of 7.54%. Insulin delivery devices lead by type with a 55.6% share, hospital pharmacies dominate distribution at 57.2%, and hospitals lead by end user at 44.5%, with Saudi Arabia holding the largest country share in 2025.
How Automated Insulin Delivery Systems are Reshaping the Future of GCC Diabetes Care Devices Market:
- The GCC's growing focus on automated insulin delivery is driving a significant shift toward next-generation pump technology, with Omnipod 5 and MiniMed 780G launching across Saudi Arabia, UAE, Kuwait, and Qatar in early 2026, both compatible with multiple CGM platforms to expand patient choice.
- Insulet Corporation officially launched the Omnipod 5 Automated Insulin Delivery System across the GCC in February 2026, introducing tubeless patch pumps with 300-unit reservoirs and 7-day wear times that integrate with continuous glucose monitors for real-time adjustments every five minutes.
- The GCC insulin pumps market continues to address a diabetes crisis affecting roughly 12.8 million adults across the region, with prevalence rates reaching 20% in some countries, among the world's highest, driving urgent demand for automated management solutions beyond traditional injections.
- Saudi Arabia's Vision 2030 healthcare transformation continued driving a 20-25% annual increase in insulin pump procurement by its Ministry of Health since 2021, with the Kingdom accounting for an estimated 35-40% of regional insulin pump unit volume in 2026.
- Innovations in AI-driven continuous glucose monitoring are gaining traction across the GCC and UAE in 2026, with the broader GCC and UAE diabetes devices market projected to grow from USD 3.35 billion in 2025 to USD 6.84 billion by 2035, reflecting substantial government funding for healthcare infrastructure.
Grab a sample PDF of this report: https://www.imarcgroup.com/gcc-diabetes-care-devices-market/requestsample
Market Growth Factors
The augmenting demand for innovative diabetes management solutions is a central driver of the market's expansion, attributable to the increasing prevalence of diabetes in the region caused by inactive lifestyles, unhealthy food patterns, and genetic predisposition. Kuwait's Dasman Diabetes Institute continues advancing research into the relationship between immunodeficiency and type 2 diabetes, strengthening diabetic-related research and collaboration worldwide.
Favorable government policies to upgrade healthcare infrastructure are reshaping the region's diabetes care landscape. Qatar's CARDIO4Cities program and National Action Plan for obesity, diabetes, and modifiable risk factors, unveiled at the World Innovation Summit for Health, aim to lower non-communicable disease mortality by 36% through 2030, supported through 58 targeted projects aligned with Qatar's National Vision 2030.
Increasing adoption of digital health solutions is creating favorable conditions for sustained market growth. Continuous glucose monitors and insulin pumps with connectivity options allow patients to share data in real-time with healthcare providers, with more than 75% of digital health buyers having increased spending on these tools in the past two years, driven by consumer demand and improved health outcomes.
Market Segmentation
Type Insights:
- Blood Glucose Monitoring (BGM) Devices (Self-Monitoring Devices, Continuous Glucose Monitoring Devices)
- Insulin Delivery Devices (Pumps, Pens, Syringes, Jet Injectors)
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
- Others
End User Insights:
- Hospitals
- Home Care
- Diagnostic Centers
- Ambulatory Surgery Centers
Country Insights:
- Saudi Arabia
- UAE
- Qatar
- Kuwait
- Oman
- Bahrain
We explore the factors propelling the GCC Diabetes Care Devices Market growth, including technological advancements, consumer behaviors, and regulatory changes.
Recent Development & News
February 2026: Insulet Corporation officially launched the Omnipod 5 Automated Insulin Delivery System across Saudi Arabia, UAE, Kuwait, and Qatar, introducing tubeless patch pump technology compatible with multiple CGM platforms to expand patient choice across the region.
April 2026: Industry analysis confirmed the GCC and UAE diabetes devices market, valued at USD 3.35 billion in 2025, is projected to reach USD 6.84 billion by 2035, driven by rising diabetes prevalence, AI-driven CGM adoption, and substantial government healthcare infrastructure funding.
If you require any specific information that is not currently covered within the scope of the report, we will provide the same as part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Comments (0)